<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alprazolam: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alprazolam: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alprazolam: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12533" href="/d/html/12533.html" rel="external">see "Alprazolam: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13346" href="/d/html/13346.html" rel="external">see "Alprazolam: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F49127843"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with opioids:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of benzodiazepines, including alprazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing alprazolam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dependence and withdrawal reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The continued use of benzodiazepines, including alprazolam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of alprazolam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam or reduce the dosage.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F132040"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ALPRAZolam Intensol;</li>
<li>ALPRAZolam XR;</li>
<li>Xanax;</li>
<li>Xanax XR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865614"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ALPRAZolam TS;</li>
<li>APO-Alpraz;</li>
<li>APO-Alpraz TS;</li>
<li>JAMP-Alprazolam [DSC];</li>
<li>PRO-Alprazolam;</li>
<li>TEVA-Alprazolam;</li>
<li>Xanax;</li>
<li>Xanax TS</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F132085"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Benzodiazepine</li></ul></div>
<div class="block doa drugH1Div" id="F132045"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Reduce dose or avoid use in patients receiving opioids or with significant chronic disease (eg, respiratory compromise). Avoid use in patients with a history of substance use, misuse of medications, or depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="681d778e-2c1e-46c3-9264-d477867f0a71">Anxiety</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Anxiety disorders (adjunctive therapy or monotherapy) (alternative agent): </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Generally used short term for symptom relief until preferred therapy (eg, serotonin reuptake inhibitor) is effective (eg, 4 to 6 weeks, followed by tapering). Long-term, low-dose therapy (eg, 2 mg/day) may be considered in select patients when other treatments are ineffective or poorly tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161'])">Ref</a></span>). Use with caution in patients with posttraumatic stress disorder; benzodiazepines may worsen symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VA.DoD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VA.DoD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i>
<b>Oral:</b> Initial: 0.25 mg 3 to 4 times daily; may increase dose based on response and tolerability in increments ≤1 mg/day at intervals ≥3 days up to a usual dose of 2 to 6 mg/day in 3 to 4 divided doses. Some patients may require up to 8 mg/day for optimal response; manufacturer's labeling maximum: 10 mg/day. With doses &gt;4 mg/day, increase more gradually to minimize adverse effects; periodically reassess and consider dosage reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.1','lexi-content-ref-35900161','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.1','lexi-content-ref-35900161','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release (panic disorder labeled use):</i>
<b>Oral:</b> Initial: 0.5 to 1 mg once daily; may increase dose based on response and tolerability in increments ≤1 mg/day at intervals ≥3 days up to a usual dose of 2 to 6 mg/day. Some patients may require up to 8 mg/day for optimal response; manufacturer's labeling maximum: 10 mg/day. With doses &gt;4 mg/day, increase more gradually to minimize adverse effects; periodically reassess and consider dosage reduction. Administration in 2 divided doses may be considered to maximize efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.1','lexi-content-ref-35900161','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.1','lexi-content-ref-35900161','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Procedural anxiety (premedication) (off-label use):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i>
<b>Oral, Sublingual:</b> 0.5 mg 30 to 90 minutes before procedure; if needed due to incomplete response and/or duration of procedure, may repeat the dose (usually at 50% of the initial dose) after 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Choy.1','lexi-content-ref-12456424','lexi-content-ref-24977401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Choy.1','lexi-content-ref-12456424','lexi-content-ref-24977401'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cafbc8a-abd9-42c0-9a5e-50ae32938929">Vertigo, acute episodes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vertigo, acute episodes (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve use for symptomatic relief of episodes lasting several hours to days (maximum duration: 3 days); chronic use may impede adaptation and recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release: </i>
<b>Oral:</b> Initial: 0.5 mg every 8 hours as needed for up to 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing conversions:</b>
<b>Immediate release to extended release:</b> ER tablet may be substituted for the IR tablet on a mg-per-mg basis, administering the ER tablet once daily. Administration of the ER formulation in 2 divided doses may be considered to maximize efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy:</b> Unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms in patients receiving therapy ≥4 weeks or as appropriate based on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Low or moderate dose, no concerns for benzodiazepine use disorder</b>
<b>:</b> Taper total daily dose by 20% to 25% every week based on response and tolerability (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-VA.DoD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended or high-dose therapy, or suspected benzodiazepine use disorder:</b> Taper total daily dose by approximately 25% every 1 to 2 weeks based on response, tolerability, and individual patient factors (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VA.DoD.2'])">Ref</a></span>). Reduce dose more rapidly in the beginning and slow the dose reduction as the taper progresses because earlier stages of withdrawal are easier to tolerate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2'])">Ref</a></span>). The optimal duration and taper increment will vary; up to 6 months may be necessary for some patients on higher doses, and a taper rate of 50% every week may be tolerated in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VA.DoD.2'])">Ref</a></span>). For benzodiazepines with half-lives significantly &lt;24 hours, including alprazolam, consider substituting an equivalent dose of a long-acting benzodiazepine to allow for a more gradual reduction in drug serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991527"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥10 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3771810','lexi-content-ref-1880224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3771810','lexi-content-ref-1880224'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: No dosage adjustment necessary; use with caution as enhanced pharmacodynamic effects (eg, psychomotor and memory impairment) may be observed in patients with end-stage kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1587068','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1587068','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Significant removal by hemodialysis is unlikely (moderately protein bound; moderate V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3771810','lexi-content-ref-1880224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3771810','lexi-content-ref-1880224'])">Ref</a></span>). Use with caution as enhanced pharmacodynamic effects (eg, psychomotor and memory impairment) may be observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1587068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1587068'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Significant removal by hemodialysis is unlikely (moderately protein bound; moderate V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: Consider administering 50% to 75% of the usual indication-specific recommended dose; in one pharmacokinetic study patients on peritoneal dialysis exhibited a higher free fraction and AUC compared to patients with normal kidney function and hemodialysis patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1880224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1880224'])">Ref</a></span>). Additionally, enhanced pharmacodynamic effects (eg, psychomotor and memory impairment) may be observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1587068','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1587068','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Drug clearance may be dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions (eg, sedation, respiratory depression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Drug clearance may be dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions (eg, sedation, respiratory depression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988911"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;">Advanced liver disease:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IR tablet, oral concentrate, orally disintegrating tablet:</i> 0.25 mg 2 to 3 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> 0.5 mg once daily</p></div>
<div class="block doe drugH1Div" id="F132046"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Avoid use; may be appropriate for severe generalized anxiety disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Immediate release: </i>
<b>Oral:</b> Use lower initial doses of 0.25 mg 2 to 3 times daily and titrate slowly; refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Extended release:</i>
<b>Oral:</b> Use lower initial doses of 0.5 mg once daily and titrate slowly; refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing conversions:</b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy: </b> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F132062"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13346" href="/d/html/13346.html" rel="external">see "Alprazolam: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>All pediatric dosing for immediate-release formulations unless otherwise specified. Titrate dose to effect; use lowest effective dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="681d778e-2c1e-46c3-9264-d477867f0a71">Anxiety</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents &lt;18 years: Limited data available: Oral: Initial: 0.005 to 0.02 mg/<b>kg</b>/dose 3 times daily; in trials, doses were rounded to nearest available tablet size (lowest available dose is 0.125 mg [<sup>1</sup>/<sub>2</sub> of 0.25 mg tablet]). May titrate at 2- to 3-day intervals in 0.125 to 0.25 mg/dose increments up to a maximum 0.06 mg/kg/<b>day</b> or 4 mg/<b>day</b>, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2228932','lexi-content-ref-3654506','lexi-content-ref-1537778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2228932','lexi-content-ref-3654506','lexi-content-ref-1537778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosing based on 2 small open-label trials (n=13, n=17) in patients diagnosed with situational anxiety, overanxious disorder, or avoidant disorder; the reported ranges were 0.375 to 3 mg/day in one trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3654506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3654506'])">Ref</a></span>) and in the other trial, 0.5 to 3.5 mg/day with a mean of 1.6 mg/day was reported and based on clinical global ratings, alprazolam appeared to be better than placebo; however, this difference was <b>not</b> statistically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1537778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1537778'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation<b> of therapy</b>:</b> Abrupt discontinuation should be avoided. Unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms in patients receiving therapy ≥4 weeks or as appropriate based on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2'])">Ref</a></span>). Daily dose must be gradually decreased no more frequently than every 3 days; however, some patients may require a slower reduction. If withdrawal symptoms occur, resume previous dose and discontinue on a less rapid schedule.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064605"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F58318224"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Pediatric-specific recommendations are not available; in adults, lower doses are suggested if advanced liver disease present.</p></div>
<div class="block arsc drugH1Div" id="F57027855"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anterograde amnesia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anterograde amnesia:</b> Benzodiazepines can impair explicit memory and produce short-term <b>anterograde amnesia</b> (ie, memory of information or events after drug administration). Retrograde amnesia (ie, events or information prior to drug administration) is unaffected. However, the magnitude of the amnesic effect from benzodiazepines differs among the various agents, depending on their pharmacokinetic/pharmacodynamic properties, route of administration, and dose. Anterograde amnesia is associated with higher doses, IV administration, and benzodiazepines with faster absorption and higher potency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27462136','lexi-content-ref-1684055','lexi-content-ref-23789008','lexi-content-ref-3558328','lexi-content-ref-1357612','lexi-content-ref-10519733','lexi-content-ref-14978513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27462136','lexi-content-ref-1684055','lexi-content-ref-23789008','lexi-content-ref-3558328','lexi-content-ref-1357612','lexi-content-ref-10519733','lexi-content-ref-14978513'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related. Benzodiazepines, including alprazolam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. The GABA-A receptor complex is composed of 5 subunits, each with multiple isoforms. Each receptor complex contains a benzodiazepine-binding site, which is classified into several types, based on the alpha subunit isoforms and clinical effects related to each type. The BZ1 receptor type, containing the alfa 1 subunit isoform, is highly concentrated in the cortex, thalamus, and cerebellum, and is responsible for benzodiazepine-associated anterograde amnesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23789008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23789008'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; during chronic benzodiazepine administration, tolerance appears to develop, and memory impairment is limited to a window of 90 minutes following each dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Specific benzodiazepine: Benzodiazepines, such as alprazolam, with a high affinity for the benzodiazepine-receptor site, are associated with a higher propensity for amnesic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112','lexi-content-ref-1357612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112','lexi-content-ref-1357612'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23789008','lexi-content-ref-6151849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23789008','lexi-content-ref-6151849'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS effects:</b> Alprazolam can cause <b>drowsiness</b>, <b>fatigue</b>, decreased alertness, and<b> confusion</b>. In addition, alprazolam has been shown to cause <b>ataxia</b> and <b>psychomotor impairment</b>. Tolerance usually develops to its sedative and psychomotor effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8204996','lexi-content-ref-27462136','lexi-content-ref-22290367','lexi-content-ref-7480549','lexi-content-ref-17219217','lexi-content-ref-2276384','lexi-content-ref-7802851','lexi-content-ref-3931145','lexi-content-ref-3114808','lexi-content-ref-22536226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8204996','lexi-content-ref-27462136','lexi-content-ref-22290367','lexi-content-ref-7480549','lexi-content-ref-17219217','lexi-content-ref-2276384','lexi-content-ref-7802851','lexi-content-ref-3931145','lexi-content-ref-3114808','lexi-content-ref-22536226'])">Ref</a></span>). Benzodiazepines, in general, are associated with an increased risk of motor vehicle accidents and falls (particularly in older adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18570226','lexi-content-ref-28539164','lexi-content-ref-22059800','lexi-content-ref-11314681','lexi-content-ref-14978513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18570226','lexi-content-ref-28539164','lexi-content-ref-22059800','lexi-content-ref-11314681','lexi-content-ref-14978513'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3114808','lexi-content-ref-14978513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3114808','lexi-content-ref-14978513'])">Ref</a></span>); benzodiazepines, including alprazolam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. Benzodiazepine-associated sedation are mediated by the alpha 1-containing GABA-A receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23789008','lexi-content-ref-21353710','lexi-content-ref-14978513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23789008','lexi-content-ref-21353710','lexi-content-ref-14978513'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Sedation (mean onset): 40 minutes following a single 1 mg oral dose of immediate release alprazolam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6152055','lexi-content-ref-14978513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6152055','lexi-content-ref-14978513'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Sedating effects:</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (benzodiazepines in general) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22059800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22059800'])">Ref</a></span>). <b>Note:</b> Conflicting data exists for alprazolam specifically (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14978513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14978513'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2276384','lexi-content-ref-3114808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2276384','lexi-content-ref-3114808'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Titrating the initial dose too rapidly (gradual titration and dividing the dosing frequently, if using the immediate release formulation, is preferred) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3114808','lexi-content-ref-14978513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3114808','lexi-content-ref-14978513'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Immediate release formulation is associated with a higher risk for sedation compared to extended release (due to lower absorption rate of the extended release resulting in peak plasma concentrations that are half those of immediate release) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11106134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11106134'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant use of other CNS depressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29385731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29385731'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Paradoxical reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paradoxical reactions</b>, sometimes referred to as disinhibitory reactions or behavioral disinhibition, have been reported in children, adults, and older adults with benzodiazepine use, particularly in those with risk factors. Reactions are relatively uncommon and have been characterized in a number of ways, including increased talkativeness, excitement, restlessness, hyperactivity, sleep disturbances, hostility, rage, agitation, and/or aggressive behavior (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138835','lexi-content-ref-12186578','lexi-content-ref-1677237','lexi-content-ref-15460178','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138835','lexi-content-ref-12186578','lexi-content-ref-1677237','lexi-content-ref-15460178','lexi-content-ref-29723722'])">Ref</a></span>). In children, paradoxical reactions to benzodiazepines, particularly midazolam, have been most commonly described as agitation, restlessness, inconsolable crying, screaming, disorientation, and/or excitement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1904374','lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1904374','lexi-content-ref-15460178'])">Ref</a></span>). Of note, alprazolam has been frequently associated with behavioral aggression in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138835','lexi-content-ref-8749839','lexi-content-ref-Bond.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138835','lexi-content-ref-8749839','lexi-content-ref-Bond.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (potentially, although may also be idiosyncratic); exact mechanism is unclear due to limited evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bond.1','lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bond.1','lexi-content-ref-15460178'])">Ref</a></span>). One hypothesis has suggested that increased GABAergic activity in the brain from benzodiazepines causes a decrease in the restraining influence of the frontal cortex, thereby causing excitement, hostility, and rage. An additional proposed mechanism is that benzodiazepines can reduce serotonergic neurotransmission, subsequently causing aggressive behavior. Another mechanism is that in select patients with genetic variations in GABA-A receptors, there is decreased GABA transmission with benzodiazepines which results in neuronal overexcitation manifested clinically as a paradoxical reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Benzodiazepines in general:</p>
<p style="text-indent:-2em;margin-left:8em;">Age-related (extremes of age):</p>
<p style="text-indent:-2em;margin-left:10em;">• Children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178','lexi-content-ref-10519733','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178','lexi-content-ref-10519733','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Disease- or condition-related:</p>
<p style="text-indent:-2em;margin-left:8em;">• Past history of aggressive behavior or violence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Alcoholism or history of alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178'])">Ref</a></span>) or social use of alcohol (on risk of aggressive behavior with alprazolam, specifically) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8410962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8410962'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric or personality disorders, including affective disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patient-related:</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic predisposition (potential risk factor) (ie, variability in the density of the GABA-benzodiazepine receptors throughout the brain, a persistence of a juvenile pattern of benzodiazepine response in adulthood, or multiple allelic forms of the receptors with varying affinities for benzodiazepines have all been suggested as potentially playing a role) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178','lexi-content-ref-29723722','lexi-content-ref-3661967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178','lexi-content-ref-29723722','lexi-content-ref-3661967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Other potential risk factors: <b>Note: </b>No established risk factors since evidence is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12186578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12186578'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (likely a risk, but not firmly established) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3137624','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3137624','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Parenteral benzodiazepine administration (potential risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific benzodiazepines (potential risk): Benzodiazepines with a higher potency (eg, alprazolam, clonazepam) and/or a short half-life (eg, alprazolam) are believed to carry an increased risk; however, it has also been suggested that there is no difference in risk among the various benzodiazepines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bond.1','lexi-content-ref-3137624','lexi-content-ref-12186578','lexi-content-ref-29723722','lexi-content-ref-10653202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bond.1','lexi-content-ref-3137624','lexi-content-ref-12186578','lexi-content-ref-29723722','lexi-content-ref-10653202'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome:</b> Therapeutic use of benzodiazepines, including alprazolam, is associated with a <b>withdrawal syndrome </b>in children and adults<b>, </b>particularly following abrupt or overly rapid discontinuation following regular use. Benzodiazepine-associated withdrawal symptoms can include new withdrawal symptoms or rebound symptoms, both of which are typically transient, short-lasting, and reversible. A persistent post-withdrawal disorder, which can be long-lasting, severe, and potentially irreversible, has also been described. In general, withdrawal symptoms are typically mild and characterized as anxiety, panic attacks, restlessness, insomnia and other sleep disturbances, irritability, poor concentration, confusion, nausea/vomiting, weight loss, tremor, diaphoresis, tachycardia, and muscle pain/stiffness. Severe symptoms such as seizure and psychosis may also rarely occur following abrupt discontinuation. Severe withdrawal may be fatal. Data are limited on persistent post-withdrawal disorders, but cognitive impairment; depression; anxiety; sensory disturbances (eg, tinnitus, paresthesia, skin sensations); motor disturbances (eg, muscle pain, weakness, spasms); and GI disturbances have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3092053','lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-3535544','lexi-content-ref-10519733','lexi-content-ref-8145176','lexi-content-ref-29851670','lexi-content-ref-2307974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3092053','lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-3535544','lexi-content-ref-10519733','lexi-content-ref-8145176','lexi-content-ref-29851670','lexi-content-ref-2307974'])">Ref</a></span>). For alprazolam specifically, there are also rare case reports of new-onset withdrawal <b>catatonia</b> occurring after abrupt withdrawal of chronic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26949118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26949118'])">Ref</a></span>). Severity, onset, and duration of any benzodiazepine withdrawal syndrome varies based on several factors, such as specific benzodiazepine administered (and its half-life), dose, and duration of use. However, in general, new withdrawal symptoms typically resolve within 2 to 4 weeks and rebound symptoms may last 3 weeks, but persistent post-withdrawal symptoms may last &gt;6 weeks and take 6 to 12 months to completely resolve, and in some cases, persist for years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112','lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112','lexi-content-ref-32259826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; exact mechanisms are complex and unclear, but chronic exposure to benzodiazepines alters GABAergic neurotransmission (up/down regulation of gamma-aminobutyric acid [GABA]-A receptor subunits) and rapid or abrupt withdrawal results in underactivity of inhibitory GABA functions subsequently increasing excitatory nervous activity and likely contributing to symptoms associated with withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19900604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19900604'])">Ref</a></span>). A role of glutamate receptors, including N-methyl-D aspartate (NMDA)-, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-receptors, and metabotropic glutamate (mGlu) receptors, has also been suggested. In mice and rat studies, antagonists for glutamate receptors have shown the ability to potently suppress the withdrawal signs caused by chronic benzodiazepine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12725868','lexi-content-ref-10580363','lexi-content-ref-15266351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12725868','lexi-content-ref-10580363','lexi-content-ref-15266351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset of symptoms usually occurs within the first day following abrupt withdrawal of short- acting or intermediate-acting benzodiazepines (such as alprazolam and lorazepam, respectively). Long-acting benzodiazepines (eg, diazepam, flurazepam) are usually associated with an initial onset of withdrawal symptoms 5 days following abrupt discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3092053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3092053'])">Ref</a></span>). Alprazolam may produce physical dependence after durations of only a few weeks and in doses as small as 0.75 to 1 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18750636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18750636'])">Ref</a></span>). In general, persistent post-withdrawal disorder associated with psychotropic medications (eg, benzodiazepines) have an onset ranging from 24 hours to 6 weeks following a decrease, discontinuation, or switch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Benzodiazepines in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Abrupt discontinuation (rather than gradual dosage reduction) of a benzodiazepine used long-term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3092053','lexi-content-ref-15078112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3092053','lexi-content-ref-15078112'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9559604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9559604'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Chronic dosing (ie, intermittent dosing may reduce the risk of withdrawal symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31271339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31271339'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Long treatment durations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1980689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1980689'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Withdrawal-associated seizure: Predisposed patients (eg, brain damage, alcohol abuse, history of seizure, or those taking medications that lower the seizure threshold) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Alprazolam specifically:</p>
<p style="text-indent:-2em;margin-left:8em;">• History of substance use disorder, including alcohol use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2349800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2349800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific benzodiazepine: High-potency benzodiazepines with short and intermediate half-lives generally have a higher risk for rebound, withdrawal reactions, and dependence compared to long-acting agents. Alprazolam is a high potency benzodiazepine with a short half-life and may produce more dependency and withdrawal than many other benzodiazepines. Benzodiazepines with a relatively longer half-life (usually reported at &gt;24 hours in adults), such as clonazepam, are usually associated with fewer (and potentially less severe) rebound and withdrawal symptoms, particularly if tapered appropriately (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-18750636','lexi-content-ref-10519733','lexi-content-ref-1686752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-18750636','lexi-content-ref-10519733','lexi-content-ref-1686752'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F132006"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults. [IR = Immediate release, ER = Extended release]</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (IR: 11%; ER: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (6% to 14%), weight gain (IR: 27%; ER: 5%), weight loss (IR: 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (IR: 26%; ER: 8%), decreased appetite (IR: 28%), increased appetite (IR: 33%; ER: 7%), xerostomia (IR: 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Difficulty in micturition (IR: 12%; ER: ≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia (IR: 40%; ER: 7% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Ataxia table link" class="lexi-table-link" data-table-id="lexi-content-ataxia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ataxia')">table 1</a>)</span><span class="table-link" style="display:none;">Ataxia</span>, cognitive dysfunction (IR: 29%; ER: Bradyphrenia: &lt;1%), depression (ER: 12%; depressed mood: 1%), dizziness (IR: 2% to 21%; ER: ≥1%), drowsiness (IR: 41% to 77%; ER: 23%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 2</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, dysarthria (IR: 23%; ER: 11%), fatigue (IR: 49%; ER: 14%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 3</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, irritability (IR: 33%; ER: ≥1%), memory impairment (IR: 33%; ER: 15%), sedated state (ER: 45%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ataxia" frame="border" id="lexi-content-ataxia" rules="all">
<caption style="text-align:left;">
<b>Alprazolam: Adverse Reaction: Ataxia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Alprazolam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Alprazolam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,388</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,231</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "impaired coordination"</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">531</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "coordination abnormal"</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">531</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">349</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:left;">
<b>Alprazolam: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Alprazolam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Alprazolam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">41%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Generalized anxiety</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">505</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">77%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,388</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,231</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">531</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">349</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:left;">
<b>Alprazolam: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Alprazolam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Alprazolam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">49%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,388</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,231</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">531</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">349</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (ER: ≥1%), hypotension (IR: 5%; ER: &lt;1%), palpitations (ER: ≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin reaction (IR: ≤4%), dermatitis (IR: ≤4%), diaphoresis (ER: ≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido (IR: 7%), increased libido (IR: 8%; ER: ≥1%), menstrual disease (IR: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (ER: ≥1%), anorexia (ER: 2%), diarrhea (ER: ≥1%), dyspepsia (ER: ≥1%), nausea (ER: 6%), sialorrhea (IR: 4% to 6%; ER: ≥1%), vomiting (ER: ≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (ER: 4%), sexual disorder (IR: 7%; ER: 2%), urinary incontinence (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (ER: ≥1%), akathisia (IR: 2%), asthenia (ER: ≥1%), balance impairment (ER: 3%), confusion (IR: 10%; ER: 2%)<span class="lexi-table-link-container"> (<a aria-label="Confusion table link" class="lexi-table-link" data-table-id="lexi-content-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-confusion')">table 4</a>)</span><span class="table-link" style="display:none;">Confusion</span>, decreased mental acuity (ER: 7%), depersonalization (ER: ≥1%), derealization (≥1%), disinhibition (IR: 3%), disorientation (ER: 2%), disturbance in attention (ER: 3%), feeling hot (≤1%), headache (ER: ≥1%), hypersomnia (ER: 1%), hypoesthesia (ER: 1%), insomnia (ER: ≥1%), lethargy (ER: 2%), malaise (ER: ≥1%), nervousness (ER: ≥1%), nightmares (ER: ≥1%), restlessness (ER: ≥1%), talkativeness (≤2%), tremor (ER: ≥1%), vertigo (ER: ≥1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Confusion" frame="border" id="lexi-content-confusion" rules="all">
<caption style="text-align:left;">
<b>Alprazolam: Adverse Reaction: Confusion</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Alprazolam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Alprazolam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,388</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,231</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">531</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">349</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (ER: 2%), back pain (ER: ≥1%), dyskinesia (ER: 2%), limb pain (ER: 1%), muscle cramps (ER: ≥1%), muscle twitching (ER: ≥1%), myalgia (ER: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (ER: ≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (ER: 2%), hyperventilation (ER: ≥1%), nasal congestion (ER: ≥1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest tightness (ER), edema (ER), sinus tachycardia (ER), syncope (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cold and clammy skin (ER), urticaria (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (IR), dysphagia (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (IR)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (ER), aggressive behavior (ER), amnesia (ER), apathy (ER), choking sensation (ER), clumsiness (ER), emotional lability (ER), euphoria (ER), falling (ER), hallucination, hangover effect (ER), homicidal ideation (ER), hypomania, hypotonia (ER), impaired consciousness (ER), impulse control disorder (ER), increased energy (ER), intoxicated feeling (ER), jitteriness (ER), mania, outbursts of anger (ER), paraplegia (ER), psychomotor impairment (ER), relaxation (ER), rigors (ER), seizure, sensation of cold (ER), sleep talking (ER), stupor (ER), suicidal ideation (ER), voice disorder (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (IR), mydriasis (ER), photophobia (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (ER), tinnitus (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (ER), rhinorrhea (ER), sleep apnea (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (ER)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Paresthesia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin photosensitivity (Kanwar 1990), Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (Petrić 2011; Shioiri 1996), galactorrhea not associated with childbirth (Petrić 2011; Shioiri 1996), gynecomastia, hyperprolactinemia (Shioiri 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatitis (Judd 1986), increased liver enzymes (Judd 1986), jaundice (Judd 1986)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anterograde amnesia (Curran 1994), drug abuse (Juergens 1988; Sheehan 1991), drug dependence (Juergens 1988), hostility (Rapaport 1985), withdrawal syndrome (including catatonia, rebound anxiety, and status epilepticus) (Mellman 1986; Oldham 2016; Vicente Ferreira Naves 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Paradoxical reaction (including muscle spasticity, paradoxical central nervous system stimulation, and sleep disturbance) (Kirkpatrick 2016)</p></div>
<div class="block coi drugH1Div" id="F132021"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to alprazolam, any component of the formulation, or other benzodiazepines (cross-sensitivity with other benzodiazepines may exist); concurrent therapy with strong cytochrome P-450 3A (CYP3A) inhibitors (eg, itraconazole, ketoconazole), except ritonavir; acute narrow angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Myasthenia gravis; severe hepatic insufficiency; severe respiratory insufficiency; sleep apnea.</p></div>
<div class="block war drugH1Div" id="F132003"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related activities: Hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted with benzodiazepines (Dolder 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Avoid use in patients with depression because of concerns about worsening mood symptoms, particularly if suicidal risk may be present, except for acute or emergency situations (eg, acute agitation, status epilepticus) (Craske 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment or predisposition to urate nephropathy; has weak uricosuric properties.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Flumazenil: Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; use lower starting dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult patients: Older adults may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in elderly dementia patients (Jennum 2015; Saarelainen 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• Obese patients: Use with caution in obese patients; may have prolonged action when discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">• Smokers: Cigarette smoking may decrease alprazolam concentrations up to 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse, misuse, and substance use disorder: Counsel patients at increased risk on proper use and monitoring for signs and symptoms of abuse, misuse, and substance use disorder. Institute early treatment or refer patients in whom substance use disorder is suspected. Limit dosages and durations to the minimum required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.</p>
<p style="text-indent:-2em;margin-left:4em;">• Breakthrough anxiety: At the end of dosing interval, breakthrough anxiety may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Alprazolam has a short half-life for a benzodiazepine and the duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance does not develop to the anxiolytic effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.</p></div>
<div class="block foc drugH1Div" id="F132014"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ALPRAZolam Intensol: 1 mg/mL (30 mL) [unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax: 0.25 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax: 0.5 mg [scored; contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax: 1 mg [scored; contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax: 2 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ALPRAZolam XR: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ALPRAZolam XR: 1 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ALPRAZolam XR: 2 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ALPRAZolam XR: 3 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax XR: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax XR: 1 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax XR: 2 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax XR: 3 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg, 3 mg</p></div>
<div class="block geq drugH1Div" id="F131999"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F132024"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (ALPRAZolam Intensol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $3.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (ALPRAZolam ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $2.15 - $2.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $2.67 - $2.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $3.55 - $3.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $5.32 - $5.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Xanax XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $12.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $14.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $19.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $29.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (ALPRAZolam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $1.52 - $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $1.89 - $2.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $2.52 - $3.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $4.29 - $6.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (ALPRAZolam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $0.60 - $0.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $0.76 - $0.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.96 - $1.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $1.69 - $1.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Xanax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $6.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $7.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $10.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $17.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865615"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax: 0.25 mg [contains corn starch, docusate sodium/sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax: 0.5 mg [contains corn starch, docusate sodium/sodium benzoate, fd&amp;c yellow #5 (tartrazine)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax: 1 mg [contains corn starch, docusate sodium/sodium benzoate, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xanax TS: 2 mg [contains corn starch, docusate sodium/sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg</p></div>
<div class="block csi drugH1Div" id="F132087"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block adm drugH1Div" id="F132018"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IR preparations: May be administered sublingually if oral administration is not possible; absorption and onset of effect are comparable to oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3680603','lexi-content-ref-1516609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3680603','lexi-content-ref-1516609'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: Should be taken once daily in the morning; do not crush, break, or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral concentrate: Use only the provided calibrated dropper to withdraw the prescribed dose. Mix the dose with ≥30 mL of juice or other liquid or semi-solid foods (eg, applesauce, pudding). The prepared mixture should be administered immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablets: Using dry hands, place tablet on top of tongue and allow to disintegrate. Administration with water is not necessary.</p></div>
<div class="block admp drugH1Div" id="F52612203"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate-release tablet: In adults, may be administered sublingually if oral administration is not possible; absorption and onset of effect is comparable to oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3680603','lexi-content-ref-1516609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3680603','lexi-content-ref-1516609'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral concentrate: Use only the provided calibrated dropper to withdraw the prescribed dose. Mix the dose with ≥30 mL of juice or other liquid or semi-solid foods (eg, applesauce, pudding). The prepared mixture should be administered immediately.</p></div>
<div class="block meg drugH1Div" id="F49640330"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Xanax: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F018276s059lbl.pdf%23page%3D22&amp;token=qmqAybhySUDVEdI4RuKb6Of7fIF0hVpBUTxRDEUBFZp7UcxJIpSSUfgS1NpUUiAgyCcjR%2FejtXpWTrbYvnU5Wsn9vlt2L0g8ziXdHzqiJoFbJZJ%2F1zm5VJznCQ9vLkzD&amp;TOPIC_ID=8453" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018276s059lbl.pdf#page=22</a></p>
<p style="text-indent:-2em;margin-left:4em;">Xanax XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021434s022lbl.pdf%23page%3D23&amp;token=zDwcGAz2UHqhlFbx2J3V4zao%2FluEuUnyb5XYtV8zDDbcejqTbyuLPkcSxN%2FgGOQDG%2BWfgP3RnixpDoJeYkxEzzUgSdcpIha%2FHgd4MBErLrGhc2WM8SFIoulwGd2AMvge&amp;TOPIC_ID=8453" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021434s022lbl.pdf#page=23</a></p></div>
<div class="block use drugH1Div" id="F132017"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Anxiety disorders:</b> Treatment of generalized anxiety disorder, short-term anxiety, and anxiety associated with depression (IR tablet, oral concentrate, orally disintegrating tablets); treatment of panic disorder with or without agoraphobia (IR tablet, ER tablet, oral concentrate, orally disintegrating tablets).</p></div>
<div class="block off-label drugH1Div" id="F54446051"><span class="drugH1">Use: Off-Label: Adult</span><p>Vertigo, acute episodes</p></div>
<div class="block mst drugH1Div" id="F132095"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">ALPRAZolam may be confused with alprostadil, clonazePAM, LORazepam, triazolam</p>
<p style="text-indent:-2em;margin-left:4em;">Xanax may be confused with Fanapt, Lanoxin, Tenex, Tylox, Xopenex, Zantac, ZyrTEC</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Alprazolam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to risk of abuse, misuse, physical dependence, and addiction. In addition, older adults have increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use. However, benzodiazepines may be appropriate in the elderly when used for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F132079"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F132008"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of ALPRAZolam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of ALPRAZolam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of ALPRAZolam. Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of ALPRAZolam.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Weak): May increase the serum concentration of ALPRAZolam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: May increase the serum concentration of ALPRAZolam.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ilaprazole: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May increase the serum concentration of ALPRAZolam. Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of ALPRAZolam. Management: Reduce the alprazolam dose by 50% when a patient is started on nirmatrelvir/ritonavir and alprazolam together, or when nirmatrelvir/ritonavir is initiated in a patient already treated with alprazolam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine.  Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of ALPRAZolam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of ALPRAZolam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of ALPRAZolam. Specifically, this occurs with ritonavir initiation/short-term use. Management: Reduce alprazolam dose by 50% when ritonavir and alprazolam are initiated together, or when ritonavir is initiated in a patient already treated with alprazolam. No alprazolam dose reduction required in patients taking ritonavir for more than 10 to 14 days<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Treosulfan: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F132035"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">The C<sub>max</sub> of the extended release formulation is increased by 25% when a high-fat meal is given 2 hours before dosing. T<sub>max</sub> is decreased 33% when food is given immediately prior to dose and increased by 33% when food is given ≥1 hour after dose. Management: Administer without regard to food.</p></div>
<div class="block rep_considerations drugH1Div" id="F56281225"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Amenorrhea and galactorrhea were observed in a patient following self-medication with high doses of alprazolam (alprazolam extended release 3 mg and alprazolam 5 to 6 mg daily for several months). Following a tapered withdrawal of alprazolam, prolactin levels returned to normal, regular menstrual cycles resumed, and galactorrhea resolved (Petric 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Therapy for anxiety should be individualized (BAP [McAllister-Williams 2017]); avoid the use of benzodiazepines for the treatment of anxiety disorders in patients planning to become pregnant (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Alprazolam can be detected in seminal fluid; however, alterations of the seminal profile (eg, sperm concentration, motility) were not observed in 4 patients evaluated (Mazzilli 2021).</p></div>
<div class="block pri drugH1Div" id="F132025"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Alprazolam and its metabolites cross the human placenta (García-Algar 2007).</p>
<p style="text-indent:0em;margin-top:2em;">In utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Freeman 2018; Grigoriadis 2019; Noh 2022; Szpunar 2022; Tinker 2019; Wikner 2007). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, and respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, and tremors). Data related to long-term effects on neurodevelopment are inconclusive (Chen 2022; Radojčić 2017; Sundbakk 2022; Wang 2022). Newborns exposed to alprazolam in utero should be monitored for feeding problems, respiratory depression, sedation, and withdrawal.</p>
<p style="text-indent:0em;margin-top:2em;">Therapy for anxiety during pregnancy should be individualized. Untreated or inadequately treated psychiatric illness may lead to poor adherence to prenatal care and adverse pregnancy outcomes (ACOG 2008). Benzodiazepines are not preferred when pharmacologic treatment for anxiety disorders is needed during pregnancy (BAP [McAllister-Williams 2017]; Larsen 2015) and when a benzodiazepine is needed, the use of alprazolam is not preferred. If possible, avoid scheduled doses of benzodiazepines in the month prior to delivery to reduce the risk of withdrawal symptoms in the newborn (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to alprazolam is ongoing. Health care providers are encouraged to enroll patients exposed to alprazolam during pregnancy in the National Pregnancy Registry for Psychiatric Medications (1-866-961-2388).</p></div>
<div class="block brc drugH1Div" id="F132026"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Alprazolam is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Data related to the presence of alprazolam in breast milk are available:</p>
<p style="text-indent:-2em;margin-left:4em;">• Following administration of a single oral dose of alprazolam 0.5 mg to 8 patients, 6 to 28 weeks postpartum, peak breast milk concentrations of alprazolam occurred at ~1 hour and the half-life was ~14 hours; metabolites were not detected. Peak breast milk concentrations of alprazolam (3.7 ± 1.59 ng/mL) were ~60% lower than the peak maternal serum concentration. Authors of the study calculated the relative infant dose (RID) of alprazolam via breast milk to be 3% of the weight-adjusted maternal dose (Oo 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk was collected from 2 patients, 3 to 6 days postpartum, who had been taking alprazolam during pregnancy and after delivery. Breast milk was sampled 2 hours after the maternal dose, approximately when the peak maternal plasma concentration occurs. The first patient was taking alprazolam 0.8 mg/day; the peak breast milk concentration of alprazolam was 3.4 ng/mL. The second patient was taking alprazolam 2.4 mg/day, providing a peak breast milk concentration of 24.5 ng/mL. The authors of the study calculated the RID of alprazolam via breast milk, compared to the weight-adjusted maternal dose, 2 different ways: first by using the actual amount of breast milk ingested, then by using a theoretical milk intake of 150 mL/kg/day (the average amount ingested by an exclusively breastfed infant). For the first case, the RID of alprazolam was 2% (based on actual intake) compared to 3.8% (theoretical intake). For the second case, the postpartum RID of alprazolam was 7.3% (based on actual intake) compared to 9.3% (theoretical intake). The first patient also had breast milk sampled 1.5 hours after a maternal dose of 1 mg/day at the 1-month postpartum visit. Alprazolam concentrations in breast milk at this time were 5.42 ng/mL and the RID was calculated to be 5.3% (actual intake) and 4.6% (theoretical intake) (Nishimura 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). However, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:0em;">Drowsiness, lethargy, or weight loss in breastfeeding infants has been observed in case reports following maternal use of some benzodiazepines (Iqbal 2002). Case reports have noted drowsiness (Ito 1993) or CNS depression (Kelly 2012) in infants exposed to alprazolam while breastfeeding. Symptoms of withdrawal were described in an infant following alprazolam exposure in utero and via breast milk (Anderson 1989).</p>
<p style="text-indent:0em;">Breastfeeding during benzodiazepine therapy is not recommended due to the potential for drowsiness in the breastfeeding infant (Larsen 2015); breastfeeding during alprazolam therapy is not recommended by the manufacturer. If a benzodiazepine is needed in breastfeeding patients, use of a short-acting agent is preferred (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F9405830"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Orally-disintegrating tablets may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F132011"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory and cardiovascular status; mental alertness; assess risk for abuse, misuse, and substance use disorder.</p></div>
<div class="block pha drugH1Div" id="F132002"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Short-acting benzodiazepine (Griffin 2013). Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors.</p></div>
<div class="block phk drugH1Div" id="F132020"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Readily absorbed; Extended release: Slower relative to immediate release formulation resulting in a concentration that is maintained 5 to 11 hours after dosing; rate increased following night time dosing (versus morning dosing).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Adults: Classified as a short-acting benzodiazepine; classification based on benzodiazepines with half-life between 1 and 12 hours (Griffin 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Immediate release: V<sub>d</sub>: 0.84 to 1.42 L/kg (Greenblatt 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 80%; primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4; forms two active metabolites (4-hydroxyalprazolam and α-hydroxyalprazolam [about half as active as alprazolam]) and an inactive metabolite benzophenone metabolite, however, the active metabolites are unlikely to contribute to much of the pharmacologic effects because of their low concentrations and lesser potencies.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Immediate release: 84% to 92% (Greenblatt 1993); Extended release: 90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 11.2 hours (Immediate release range: 6.3 to 26.9 hours; Extended release range: 10.7 to 15.8 hours); Orally-disintegrating tablet: Mean: 12.5 hours (range: 7.9 to 19.2 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Alcoholic liver disease: 19.7 hours (range: 5.8 to 65.3 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Obesity: 21.8 hours (range: 9.9 to 40.4 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Elderly: 16.3 hours (range: 9 to 26.9 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Adolescents and Adults: ~9 hours, relatively steady from 4 to 12 hours (Glue 2006); decreased by 1 hour when administered at bedtime (as compared to morning administration); decreased by 33% when administered with a high-fat meal; increased by 33% when administered ≥1 hour after a high-fat meal.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally-disintegrating tablet: 1.5 to 2 hours; occurs ~15 minutes earlier when administered with water; increased to ~4 hours when administered with a high-fat meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as unchanged drug and metabolites).</p></div>
<div class="block phksp drugH1Div" id="F51220148"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Maximal concentrations and half-life are approximately 15% and 25% higher in Asians.</p>
<p style="text-indent:-2em;margin-left:2em;">Cigarette smoking: Concentrations may be reduced by up to 50% in smokers.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F132027"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo alpraz | Xanax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alplax | Alprazolam Cevallo | Alprazolam denver farma | Alprazolam fabra | Alprazolam klonal | Alprazolam labsa | Alprazolam luar | Alprazolam Microsules | Alprazolam northia | Alprazolam Puntanos | Alprim | Amziax | Ansielix | Becede | Bestrol | Callpax | Calmol | Emeral | Krama | Nivelan N | Plasedan | Prenadona | Prinox | Psicosedol | Pta | Razolam | Relaxten | Retan | Rilow | Rospaz | Tensium | Tranquinal | Xanax</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Alprastad | Alprazolam Ratiopharm | Alprazolam-arcana | Xanor</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alprax | Alprazolam-bc | Alprazolam-dp | Alprazolam-Ga | Chem mart alprazolam | Cm alprazolam | Kalma | Ralozam | Tw alprazolam | Xanax | Zamhexal</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alaxen | Alpam | Alprax | Alzolam | Nixalo | Serelam | Xanax | Xiotic | Xolam | Zolax | Zolium | Zolium xr</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Alpratop | Alpraz | Alprazolam bexal | Alprazolam eurogenerics | Alprazolam mithra pharmaceut. | Alprazolam Mylan | Alprazolam Ratiopharm | Alprazolam sandoz | Alprazolam teva generics belg | Alprazomed | Arivics | Docalprazo | Topazolam | Xanax</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Alpraz | Xanax</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Frontin | Maprazax | Sophanax | Xanax sr</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alfron | Altrox | Apraz | Constante | Frontal | Frontal xr | Teufron | Tranquinal | Zoldac</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Xanax</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Alpraz | Stresof | Xanax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Adax | Ansiopax | Grifoalpram | Prazam | Sanerva | Tricalma | Zotran</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jia le ding</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alprasyn | Benzolam | Dixin | Nirvan | Tensivan | Tranquinal | Tricalma | Xanax</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam aurovitas | Alprazolam orion | Alprox | Frontin | Helex | Neurol | Xanax</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam 1 A Pharma | Alprazolam hexal | Alprazolam Ratiopharm | Alprazolam sandoz | Cassadan | Esparon | Tafil | Xanax</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Almir | Alplax | Alprazolam lam | Angiozil | Daclor | Duazolam | Kentium | Meprax | Nervus | Pazolan | Tafil | Tapofen | Tensivan | Tranquinal</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Adax | Alprazolam la sante | Alprazolan | Alzam | Ansiolit | Biofree | Grifoalpram | Librazolam | Tranquinal | Xanax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam krka | Alprazolam orion | Alprazolam sandoz | Alprox | Xanax</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alpracid | Alprax | Alpraz | Anxigo | Prazolam | Prazonex | Restolam | Tibazolax | Xanax | Zolam | Zolapar</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam alter | Alprazolam aurobindo | Alprazolam aurovitas | Alprazolam bayvit | Alprazolam cinfa | Alprazolam combix | Alprazolam Diasa | Alprazolam edigen | Alprazolam esteve | Alprazolam kern | Alprazolam krka | Alprazolam mabo | Alprazolam neuraxpharm | Alprazolam normon | Alprazolam Pharmagenus | Alprazolam Qualix | Alprazolam Ranbaxy | Alprazolam Ratiopharm | Alprazolam Tarbis | Alprazolam tecnigen | Trankimazin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam Alternova | Alprazolam Generics | Alprazolam krka | Alprazolam Merck NM | Alprazolam sandoz | Alprox | Xanor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam almus | Alprazolam alter | Alprazolam Arrow | Alprazolam Biogaran | Alprazolam cristers | Alprazolam g gam | Alprazolam gnr | Alprazolam hcs | Alprazolam irex | Alprazolam isomed | Alprazolam merck | Alprazolam Ratiopharm | Alprazolam rpg | Alprazolam sandoz | Alprazolam Teva | Alprazolam zentiva | Alprazolam zydus | Xanax</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Xanax</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam/aurobindo | Alprazolam/gerard | Antanax | Saturnil | Xanax</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alprax | Nalion | Vick Alprazolam | Xanax</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Helex | Misar | Xanax | Xanax sr</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam orion | Alprazolam sandoz | Alprox | Apo-Alpraz | Frontin | Huma-alprazol | Xanax sr</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Actazolam | Alganax | Alprazolam OGB Mersi | Alviz | Apazol | Calmlet | Feprax | Frixitas | Grazolam | Opizolam | Xanax | Zolastin | Zypraz</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam krka | Alprox | Calmax | Gerax | Xanax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Alpralid | Alprox | Apox | Xanagis | Xanax</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aaram | Alam | Alap | Alcalm | Aleez | Alep | Algo | Alltop | Almax | Alp | Alpaz | Alpon | Alpradol | Alpram | Alpramed | Alpraquil | Alprasant | Alprastan | Alprax | Alprazone | Alprocontin | Alproenar | Alprolife | Alpronat | Alprose | Alprozam | Alrex | Alzac | Alzam | Alzex | Alzid | Alzin | Alzo | Alzokam | Alzolam | Alzolex | Alzolite | Alzomax | Alzonex | Alzopax | Alzoplex | Alzot | Anax | Ancolam | Andenax | Anxeron | Anxicalm | Anxico | Anxigon | Anxilet | Anxinil | Anxit | Anxitab | Anxorel | Anxyl | Anzilum | Anzofree | Ateez | Atrest | Balmusa | Besquil | Bio zolam | Bliz | Coolam | Copax | D.d.lam | Deproz | Dial | Eldezolam | Eureplax | Exal | Fad | Fitkul | Galprex | Halozam | Jolistar | Kaprolam | Lam | Lampose | Lazolam | Luzarn | Lypraz | Manorest | Medizolam | Meriproz | Nitril | Notence | Pacific | Pacyl | Pizolam | Plaxid | Poize | Praxal | Praz | Prazolam | Procalm | Prolam | Quiet | Razolam | Restyl | Rian | Runrest | Salirest | Shanti | Sinzolam | Sleepam | Solace | Somnia | Sowel | Stresease | Stresnil rf | Synozolam | Tagat | Tenan | Tenscure | Tensimate | Tensyl | Texidep | Texina | Tiox | Tranax | Tranisol | Trans | Tre | Trika | Troycalm | Visram | Welnorm | Xanti | Xycalm | Zallpam | Zam | Zamitol | Zecalm | Zeftra | Zenax | Zenoprax | Zocam | Zodia ds | Zolam | Zolax | Zoldac | Zolent | Zolin | Zolipax | Zoloid | Zomark | Zopax | Zopic | Zorax | Zozo</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Tafil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alpravecs | Alprazig | Alprazolam Actavis | Alprazolam alter | Alprazolam aurobindo | Alprazolam Doc | Alprazolam eg | Alprazolam krka | Alprazolam Mylan | Alprazolam sandoz | Alprazolam sigma tau | Frontal | Mialin | Valeans | Xanax</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Alpranax | Prazin | Xanax | Zolam | Zolaram | Zolarem</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Azolitan | Calmdown | Constan | Medepolin | Menbit | Solanax | Wideslow</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alzolam | Atrest | Poex | Xanax | Zolaram</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alexan | Alpram | Alpranaks | Alpranax | Alzax | Anex | Azolac | Jeil alprazolam | Sapram | Xanax | Xyren | Zacetin | Zanapam</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo alpraz | Xanax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alprox | Apo alpraz | Pazolam | Tranquinal | Xanax | Zolarem</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam ingen | Alprazolam orion | Cassadan | Frontin | Helex | Neurol | Xanax | Zomiren</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Alpraz | Alprazolam eg | Alprazolam Mithra | Docalprazo | Xanax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam orion | Alprazolams | Alprox | Frontin | Helex | Neurol | Xanax</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Alpraz | Alprazolam win | Xanax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alamsid | Alprazolam gi prot | Alzam | Amsotazona | Farmapram | Furgilim | Neupax | Noxeprom | Pisalpra | Suntazun | Tafil | Tafil ap | Tazun | Torantsita | Xanax | Zamoprax</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alpraline | Alpranax | Apo-Alpraz | Asolan | Inzolam | Prazovex | Xanapam | Xanax | Zovex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam Actavis | Alprazolam dum | Alprazolam kwk | Alprazolam Ratiopharm | Xanax</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alprozolam | Xanax | Xanor</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow Alprazolam | Xanax</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alpaz | Grifoalpram | Labox | Laboxut | Pazolam | Relaxol | Serenil | Tranquinal | Tricalma | Xanax | Zopral</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Altraxic | Altrox | Axal | Xanor | Xanor xr | Zolgen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aloram | Alp | Alpax | Alpram | Alprazom | Alprox | Altanid | Alz | Alzolam | Anpra | Anrid | Anxnil | Anzilum | Arnax | Axal | Azolam | Azolex | Bizolam | Brnax | Crozam | Enzo | Hilaxin | Jibrone | Lampro | Lapranx | Lydia | M Zolam | Mazolam | Medilap | Nax | Neram | Nervin | Neuxam | Noxalam | Onax | Pinix | Pralzo | Pranax | Praz | Prazolam | Prolam | Prozam | Razlam | Rosam | Shenlax | Syms | Tasolam | Xanax | Xylepam | Zanac | Zenith | Zolarem</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Afobam | Alpragen | Alprazolam aurovitas | Alprazomerck | Alprox | Neurol | Tafil | Xanax | Zomiren</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam er | Niravam | Xanax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam labesfal | Alprazolam Merck genericos | Alprazolam Ratiopharm | Alprazolam sandoz | Alprazolam tad | Alprazolam vitoria | Alprazolam Wynn | Alpronax | Pazolam | Prazam | Unilan | Xanax</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aceprax | Almosedan | Alplax | Alpranest | Alprazolam incomex | Alprazolam la sante | Alprazolam natrodale | Alprazolam pasteur | Alprazolam phi | Alprazolam polimed | Alzolam | Grifoalpran | Moderane | Moderex | Moderex retard | Neurozepan md | Psicozolam | Sedaler | Sedatival | Sedipral | Sedo aportil | Sedocalcio aportil | Sensitral | Todotranqui | Tranquinal | Tresanil | Tri neurin | Tricalma</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apo-Alpraz | Xanax</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam atb | Alprazolam lph | Alprox | Frontin | Helex | Prazolex | Xanax | Zolarem</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alzolam | Cassadan | Helex | Neurol | Xanax | Zoldac | Zolomaks</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Xanax | Zolam</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alpralid | Alprazolam Alternova | Alprazolam krka | Alprazolam Merck NM | Alprazolam Mylan | Alprazolam orion | Alprazolam sandoz | Alprazolam Stada | Xanor</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alzolam | Apo-Alpraz | Xanax | Zacetin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Helex | Maprazax | Xanax</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alprazolam orion | Frontin | Helex | Neurol | Xanax</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alcelam | Alnax | Alpramed | Anax | Anpress | Dizolam | Farzolam | Inzolam | Manex | Marzolam | Mitranax | Moxinax | Pharnax | Prazol | Siampraxol | Xanacine | Xanax | Xiemed | Zolam</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Prazine | Xanax</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ansiox | Stabina | Xanax</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alpragin | Alpraline | Alprox | Amprazo | Aprazo | Gendergin | Kalma | Kinax | Vanipen | Xanax</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Xanax</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Alprazec</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aceprax | Akrozolam | Alplacin | Alplacin digest | Alplacin xr | Ansionil | Kentium | Ondil | Tranquinal | Tresanil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Abaxon | Alpram | Alpramack | Ansilan | Caplam | Danox | Logat | Tafil | Tagut</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco alzam | Alzam | Apo-alprazolam | Azor | Cpl alliance alprazolam | Merck-alprazolam | Novapraz xr | Panix | Xanolam | Xanor | Zopax</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Manorest</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27138835">
<a name="27138835"></a>Albrecht B, Staiger PK, Hall K, Kambouropoulos N, Best D. Motivational drive and alprazolam misuse: A recipe for aggression? <i>Psychiatry Res</i>. 2016;240:381-389. doi:10.1016/j.psychres.2016.04.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/27138835/pubmed" id="27138835" target="_blank">27138835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12725868">
<a name="12725868"></a>Allison C, Pratt JA. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. <i>Pharmacol Ther</i>. 2003;98(2):171-195. doi:10.1016/s0163-7258(03)00029-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/12725868/pubmed" id="12725868" target="_blank">12725868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alprazolam.1">
<a name="Alprazolam.1"></a>Alprazolam Intensol oral solution (concentrate) [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alprazolam.2">
<a name="Alprazolam.2"></a>Alprazolam orally disintegrating tablets [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alprazolam.3">
<a name="Alprazolam.3"></a>Alprazolam orally disintegrating tablets [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin No. 92: Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol</i>. 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2763587">
<a name="2763587"></a>Anderson PO, McGuire GG. Neonatal alprazolam withdrawal--possible effects of breast feeding. <i>DICP</i>. 1989;23(7-8):614.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/2763587/pubmed" id="2763587" target="_blank">2763587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19900604">
<a name="19900604"></a>Authier N, Balayssac D, Sautereau M, et al. Benzodiazepine dependence: focus on withdrawal syndrome. <i>Ann Pharm Fr</i>. 2009;67(6):408-413. doi:10.1016/j.pharma.2009.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/19900604/pubmed" id="19900604" target="_blank">19900604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders.<i> World J Biol Psychiatry</i>. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23044244">
<a name="23044244"></a>Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. <i>Gen Hosp Psychiatry</i>. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/23044244/pubmed" id="23044244" target="_blank">23044244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2228932">
<a name="2228932"></a>Bernstein GA, Garfinkel BD, Borchardt CM. Comparative studies of pharmacotherapy for school refusal. <i>J Am Acad Child Adolesc Psychiatry</i>. 1990;29(5):773-781. doi:10.1097/00004583-199009000-00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/2228932/pubmed" id="2228932" target="_blank">2228932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28248609">
<a name="28248609"></a>Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). <i>Otolaryngol Head Neck Surg</i>. 2017;156(suppl 3):S1‐S47. doi:10.1177/0194599816689667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/28248609/pubmed" id="28248609" target="_blank">28248609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8749839">
<a name="8749839"></a>Bond AJ, Curran HV, Bruce MS, O'Sullivan G, Shine P. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. <i>J Affect Disord</i>. 1995;35(3):117-123. doi:10.1016/0165-0327(95)00053-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/8749839/pubmed" id="8749839" target="_blank">8749839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bond.1">
<a name="Bond.1"></a>Bond AJ. Drug-induced behavioural disinhibition: Incidence, mechanisms and therapeutic implications. <i>CNS Drugs</i>. 1998;9(1):41-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/Bond.1/pubmed" id="Bond.1" target="_blank">Bond.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8410962">
<a name="8410962"></a>Bond AJ, Silveira JC. The combination of alprazolam and alcohol on behavioral aggression. <i>J Stud Alcohol Suppl</i>. 1993;11:30-39. doi:10.15288/jsas.1993.s11.30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/8410962/pubmed" id="8410962" target="_blank">8410962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3137624">
<a name="3137624"></a>Bond A, Lader M. Differential effects of oxazepam and lorazepam on aggressive responding. <i>Psychopharmacology (Berl)</i>. 1988;95(3):369-373. doi:10.1007/BF00181949<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3137624/pubmed" id="3137624" target="_blank">3137624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11106134">
<a name="11106134"></a>Busto UE, Kaplan HL, Wright CE, et al. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. <i>J Clin Psychopharmacol</i>. 2000;20(6):628-635. doi:10.1097/00004714-200012000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/11106134/pubmed" id="11106134" target="_blank">11106134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3092053">
<a name="3092053"></a>Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. <i>N Engl J Med</i>. 1986;315(14):854-859. doi:10.1056/NEJM198610023151403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3092053/pubmed" id="3092053" target="_blank">3092053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9559604">
<a name="9559604"></a>Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. <i>Crit Care Med</i>. 1998 Apr;26(4):676-684. doi:10.1097/00003246-199804000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/9559604/pubmed" id="9559604" target="_blank">9559604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8204996">
<a name="8204996"></a>Cassano GB, Toni C, Petracca A, et al. Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. <i>Eur Neuropsychopharmacol</i>. 1994;4(1):47-53. doi:10.1016/0924-977x(94)90314-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/8204996/pubmed" id="8204996" target="_blank">8204996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36413366">
<a name="36413366"></a>Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention-deficit/hyperactivity disorders. <i>JAMA Netw Open</i>. 2022;5(11):e2243282. doi:10.1001/jamanetworkopen.2022.43282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/36413366/pubmed" id="36413366" target="_blank">36413366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15078112">
<a name="15078112"></a>Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. <i>J Clin Psychiatry</i>. 2004;(65 Suppl 5):7-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/15078112/pubmed" id="15078112" target="_blank">15078112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27462136">
<a name="27462136"></a>Chowdhury ZS, Morshed MM, Shahriar M, Bhuiyan MA, Islam SM, Bin Sayeed MS. The effect of chronic alprazolam intake on memory, attention, and psychomotor performance in healthy human male volunteers. <i>Behav Neurol</i>. 2016;2016:3730940. doi:10.1155/2016/3730940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/27462136/pubmed" id="27462136" target="_blank">27462136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Choy.1">
<a name="Choy.1"></a>Choy Y. Acute procedural anxiety and specific phobia of clinical procedures in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1904374">
<a name="1904374"></a>Commander M, Green SH, Prendergast M. Behavioural disturbances in children treated with clonazepam. <i>Dev Med Child Neurol</i>. 1991;33(4):362-363. doi:10.1111/j.1469-8749.1991.tb14889.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1904374/pubmed" id="1904374" target="_blank">1904374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32259826">
<a name="32259826"></a>Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. <i>Psychother Psychosom</i>. 2020;89(5):283-306. doi:10.1159/000506868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/32259826/pubmed" id="32259826" target="_blank">32259826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.1">
<a name="Craske.1"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1684055">
<a name="1684055"></a>Curran HV. Benzodiazepines, memory and mood: a review. <i>Psychopharmacology (Berl)</i>. 1991;105(1):1-8. doi: 10.1007/BF02316856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1684055/pubmed" id="1684055" target="_blank">1684055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7892364">
<a name="7892364"></a>Curran HV, Bond A, O'Sullivan G, et al. Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. <i>Psychol Med</i>. 1994;24(4):969-976. doi:10.1017/s0033291700029056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/7892364/pubmed" id="7892364" target="_blank">7892364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18570226">
<a name="18570226"></a>Dawson J, Boyle J, Stanley N, Johnsen S, Hindmarch I, Skene DJ. Benzodiazepine-induced reduction in activity mirrors decrements in cognitive and psychomotor performance. <i>Hum Psychopharmacol</i>. 2008;23(7):605-613. doi:10.1002/hup.961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/18570226/pubmed" id="18570226" target="_blank">18570226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12456424">
<a name="12456424"></a>De Witte JL, Alegret C, Sessler DI, Cammu G. Preoperative alprazolam reduces anxiety in ambulatory surgery patients: a comparison with oral midazolam. <i>Anesth Analg.</i> 2002;95(6):1601-1606.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/12456424/pubmed" id="12456424" target="_blank">12456424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28539164">
<a name="28539164"></a>Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: a systematic review. <i>Maturitas</i>. 2017;101:17-22. doi:10.1016/j.maturitas.2017.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/28539164/pubmed" id="28539164" target="_blank">28539164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2349800">
<a name="2349800"></a>Dickinson B, Rush PA, Radcliffe AB. Alprazolam use and dependence. A retrospective analysis of 30 cases of withdrawal. <i>West J Med</i>. 1990;152(5):604-608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/2349800/pubmed" id="2349800" target="_blank">2349800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18998740">
<a name="18998740"></a>Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. <i>CNS Drugs.</i> 2008;22(12):1021-1036. doi:10.2165/0023210-200822120-00005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/18998740/pubmed" id="18998740" target="_blank">18998740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22290367">
<a name="22290367"></a>Ellinwood EH Jr, Nikaido AM, Gupta SK, Heatherly DG, Hege S. Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam. <i>J Psychopharmacol</i>. 1993;7(1 Suppl):24-32. doi:10.1177/0269881193007001051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/22290367/pubmed" id="22290367" target="_blank">22290367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7480549">
<a name="7480549"></a>Fleishaker JC, Garzone PD, Chambers JH, Sirocco K, Weingartner H. Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects. <i>Psychopharmacology (Berl)</i>. 1995;120(2):169-176. doi:10.1007/BF02246190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/7480549/pubmed" id="7480549" target="_blank">7480549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29958100">
<a name="29958100"></a>Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders. <i>Gen Hosp Psychiatry</i>. 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/29958100/pubmed" id="29958100" target="_blank">29958100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furman.1">
<a name="Furman.1"></a>Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17453885">
<a name="17453885"></a>García-Algar O, López-Vílchez MA, Martín I, et al. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. <i>Clin Toxicol (Phila)</i>. 2007;45(3):295-298. doi:10.1080/15563650601072191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/17453885/pubmed" id="17453885" target="_blank">17453885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16988537">
<a name="16988537"></a>Glue P, Fang A, Gandelman K, et al, “Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR) in Healthy Normal Adolescent and Adult Volunteers,” <i>Am J Ther</i>, 2006, 13(5):418-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/16988537/pubmed" id="16988537" target="_blank">16988537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3567983">
<a name="3567983"></a>Greenberg DB, Surman OS, Clarke J, Baer L. Alprazolam for phobic nausea and vomiting related to cancer chemotherapy. <i>Cancer Treat Rep</i>. 1987;71(5):549‐550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3567983/pubmed" id="3567983" target="_blank">3567983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8513649">
<a name="8513649"></a>Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam. Therapeutic implications. <i>Clin Pharmacokinet</i>.1993;24(6):453-471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/8513649/pubmed" id="8513649" target="_blank">8513649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789008">
<a name="23789008"></a>Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. <i>Ochsner J</i>. 2013;13(2):214-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/23789008/pubmed" id="23789008" target="_blank">23789008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31294935">
<a name="31294935"></a>Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. <i>J Clin Psychiatry</i>. 2019;80(4):18r12412. doi:10.4088/JCP.18r12412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/31294935/pubmed" id="31294935" target="_blank">31294935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29385731">
<a name="29385731"></a>Guina J, Merrill B. Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. <i>J Clin Med</i>. 2018;7(2):17. doi:10.3390/jcm7020017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/29385731/pubmed" id="29385731" target="_blank">29385731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28759346">
<a name="28759346"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240‐3261. doi:10.1200/JCO.2017.74.4789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/28759346/pubmed" id="28759346" target="_blank">28759346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773648">
<a name="11773648"></a>Iqbal MM, Sobhan T, Ryals T, et al. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. <i>Psychiatr Serv</i>. 2002;53(1):39-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/11773648/pubmed" id="11773648" target="_blank">11773648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26342397">
<a name="26342397"></a>Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. <i>Eur Neuropsychopharmacol.</i> 2015;25(11):1906-1913. doi: 10.1016/j.euroneuro.2015.08.014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/26342397/pubmed" id="26342397" target="_blank">26342397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2869702">
<a name="2869702"></a>Judd FK, Norman TR, Marriott PF, Burrows GD. A case of alprazolam-related hepatitis. <i>Am J Psychiatry</i>. 1986;143(3):388-389. doi:10.1176/ajp.143.3.388b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/2869702/pubmed" id="2869702" target="_blank">2869702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3258735">
<a name="3258735"></a>Juergens SM, Morse RM. Alprazolam dependence in seven patients. <i>Am J Psychiatry</i>. 1988;145(5):625-627. doi:10.1176/ajp.145.5.625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3258735/pubmed" id="3258735" target="_blank">3258735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12186578">
<a name="12186578"></a>Kalachnik JE, Hanzel TE, Sevenich R, Harder SR. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. <i>Am J Ment Retard</i>. 2002;107(5):376-410. doi:10.1352/0895-8017(2002)107&lt;0376:BBSERA&gt;2.0.CO;2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/12186578/pubmed" id="12186578" target="_blank">12186578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2394310">
<a name="2394310"></a>Kanwar AJ, Gupta R, Das Mehta S, Kaur S. Photosensitivity due to alprazolam. <i>Dermatologica</i>. 1990;181(1):75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/2394310/pubmed" id="2394310" target="_blank">2394310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22504099">
<a name="22504099"></a>Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. <i>J Pediatr</i>. 2012;161(3):448-451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/22504099/pubmed" id="22504099" target="_blank">22504099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27092285">
<a name="27092285"></a>Kirkpatrick D, Smith T, Kerfeld M, Ramsdell T, Sadiq H, Sharma A. Paradoxical reaction to alprazolam in an elderly woman with a history of anxiety, mood disorders, and hypothyroidism. <i>Case Rep Psychiatry</i>. 2016;2016:6748947. doi:10.1155/2016/6748947<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/27092285/pubmed" id="27092285" target="_blank">27092285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3558328">
<a name="3558328"></a>Kumar R, Mac DS, Gabrielli WF Jr, Goodwin DW. Anxiolytics and memory: a comparison of lorazepam and alprazolam. <i>J Clin Psychiatry</i>. 1987;48(4):158-160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3558328/pubmed" id="3558328" target="_blank">3558328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21714826">
<a name="21714826"></a>Lader M. Benzodiazepines revisited--will we ever learn? <i>Addiction</i>. 2011;106(12):2086‐2109. doi:10.1111/j.1360-0443.2011.03563.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/21714826/pubmed" id="21714826" target="_blank">21714826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35548333">
<a name="35548333"></a>Lee H, Koh JW, Kim YA, et al. Pregnancy and neonatal outcomes after exposure to alprazolam in pregnancy. <i>Front Pharmacol</i>. 2022;13:854562. doi:10.3389/fphar.2022.854562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/35548333/pubmed" id="35548333" target="_blank">35548333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17219217">
<a name="17219217"></a>Leufkens TR, Vermeeren A, Smink BE, van Ruitenbeek P, Ramaekers JG. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. <i>Psychopharmacology (Berl)</i>. 2007;191(4):951-959. doi:10.1007/s00213-006-0669-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/17219217/pubmed" id="17219217" target="_blank">17219217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2276384">
<a name="2276384"></a>Linnoila M, Stapleton JM, Lister R, et al. Effects of single doses of alprazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. <i>Eur J Clin Pharmacol</i>. 1990;39(1):21-28. doi:10.1007/BF02657051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/2276384/pubmed" id="2276384" target="_blank">2276384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1677237">
<a name="1677237"></a>Little JD, Taghavi EH. Disinhibition after lorazepam augmentation of antipsychotic medication. <i>Am J Psychiatry</i>. 1991;148(8):1099-1100. doi:10.1176/ajp.148.8.1099a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1677237/pubmed" id="1677237" target="_blank">1677237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15460178">
<a name="15460178"></a>Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. <i>Pharmacotherapy</i>. 2004;24(9):1177-1185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/15460178/pubmed" id="15460178" target="_blank">15460178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33776918">
<a name="33776918"></a>Mazzilli R, Curto M, De Bernardini D, et al. Psychotropic drugs levels in seminal fluid: a new therapeutic drug monitoring analysis? <i>Front Endocrinol (Lausanne)</i>. 2021;12:620936. doi:10.3389/fendo.2021.620936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/33776918/pubmed" id="33776918" target="_blank">33776918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440103">
<a name="28440103"></a>McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. <i>J Psychopharmacol</i>. 2017;31(5):519-552. doi:10.1177/0269881117699361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/28440103/pubmed" id="28440103" target="_blank">28440103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1357612">
<a name="1357612"></a>Mejo SL. Anterograde amnesia linked to benzodiazepines. <i>Nurse Pract</i>. 1992;17(10):44, 49-50. doi:10.1097/00006205-199210000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1357612/pubmed" id="1357612" target="_blank">1357612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3535544">
<a name="3535544"></a>Mellman TA, Uhde TW. Withdrawal syndrome with gradual tapering of alprazolam. <i>Am J Psychiatry</i>. 1986;143(11):1464-1466. doi:10.1176/ajp.143.11.1464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3535544/pubmed" id="3535544" target="_blank">3535544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18750636">
<a name="18750636"></a>Mohns EB. Discontinuation and withdrawal problems of alprazolam. <i>West J Med</i>. 1989;151(3):312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/18750636/pubmed" id="18750636" target="_blank">18750636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519733">
<a name="10519733"></a>Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. <i>Can J Clin Pharmacol.</i> 1999;6(2):69-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/10519733/pubmed" id="10519733" target="_blank">10519733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Niravam.1">
<a name="Niravam.1"></a>Niravam orally disintegrating tablets (alprazolam) [prescribing information]. Philadelphia, PA: Azur Pharma, Inc; January 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33449825">
<a name="33449825"></a>Nishimura A, Furugen A, Umazume T, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. <i>Breastfeed Med</i>. 2021;16(5):424-431. doi:10.1089/bfm.2020.0259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/33449825/pubmed" id="33449825" target="_blank">33449825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35235572">
<a name="35235572"></a>Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea. <i>PLoS Med</i>. 2022;19(3):e1003945. doi:10.1371/journal.pmed.1003945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/35235572/pubmed" id="35235572" target="_blank">35235572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1980689">
<a name="1980689"></a>Nutt DJ. Pharmacological mechanisms of benzodiazepine withdrawal. <i>J Psychiatr Res</i>. 1990;24(Suppl 2):105-110. doi:10.1016/0022-3956(90)90041-n<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1980689/pubmed" id="1980689" target="_blank">1980689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3771810">
<a name="3771810"></a>Ochs HR, Greenblatt DJ, Labedzki L, Smith RB. Alprazolam kinetics in patients with renal insufficiency. <i>J Clin Psychopharmacol</i>. 1986;6(5):292-294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3771810/pubmed" id="3771810" target="_blank">3771810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26949118">
<a name="26949118"></a>Oldham MA, Desan PH. Alcohol and sedative-hypnotic withdrawal catatonia: two case reports, systematic literature review, and suggestion of a potential relationship with alcohol withdrawal delirium. <i>Psychosomatics</i>. 2016;57(3):246-255. doi:10.1016/j.psym.2015.12.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/26949118/pubmed" id="26949118" target="_blank">26949118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8527284">
<a name="8527284"></a>Oo CY, Kuhn RJ, Desai N, et al. Pharmacokinetics in Lactating Women: Prediction of Alprazolam Transfer Into Milk. <i>Br J Clin Pharmacol</i>. 1995;40(3):231-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/8527284/pubmed" id="8527284" target="_blank">8527284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7802851">
<a name="7802851"></a>O'Sullivan GH, Noshirvani H, Başoğlu M, et al. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. <i>Br J Psychiatry</i>. 1994;165(1):79-86. doi:10.1192/bjp.165.1.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/7802851/pubmed" id="7802851" target="_blank">7802851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park TW. Benzodiazepine use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8145176">
<a name="8145176"></a>Pecknold JC. Discontinuation reactions to alprazolam in panic disorder. <i>J Psychiatr Res</i>. 1993;27(Suppl 1):155-170. doi:10.1016/0022-3956(93)90025-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/8145176/pubmed" id="8145176" target="_blank">8145176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21448116">
<a name="21448116"></a>Petrić D, Peitl MV, Peitl V. High doses alprazolam induced amenorrhoea and galactorrhoea. <i>Psychiatr Danub</i>. 2011;23:123-124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/21448116/pubmed" id="21448116" target="_blank">21448116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3654506">
<a name="3654506"></a>Pfefferbaum B, Overall JE, Boren HA, et al, “Alprazolam in the Treatment of Anticipatory and Acute Situational Anxiety in Children With Cancer,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1987, 26(4):532-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3654506/pubmed" id="3654506" target="_blank">3654506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28259732">
<a name="28259732"></a>Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. <i>Neurotoxicol Teratol</i>. 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/28259732/pubmed" id="28259732" target="_blank">28259732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2857070">
<a name="2857070"></a>Rapaport M, Braff DL. Alprazolam and hostility. <i>Am J Psychiatry</i>. 1985;142(1):146. doi:10.1176/ajp.142.1.146a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/2857070/pubmed" id="2857070" target="_blank">2857070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8315437">
<a name="8315437"></a>Razavi D, Delvaux N, Farvacques C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. <i>J Clin Oncol</i>. 1993;11(7):1384‐1390. doi:10.1200/JCO.1993.11.7.1384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/8315437/pubmed" id="8315437" target="_blank">8315437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29723722">
<a name="29723722"></a>Reddy MSS, Achary U, Harbishettar V, Sivakumar PT, Varghese M. Paradoxical reaction to benzodiazepines in elderly - case series. <i>Asian J Psychiatr</i>. 2018;35:8-10. doi:10.1016/j.ajp.2018.04.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/29723722/pubmed" id="29723722" target="_blank">29723722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6151849">
<a name="6151849"></a>Roth T, Roehrs T, Wittig R, Zorick F. Benzodiazepines and memory. <i>Br J Clin Pharmacol</i>. 1984;18(Suppl 1):45S-49S. doi:10.1111/j.1365-2125.1984.tb02581.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/6151849/pubmed" id="6151849" target="_blank">6151849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653202">
<a name="10653202"></a>Rothschild AJ, Shindul-Rothschild JA, Viguera A, Murray M, Brewster S. Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. <i>J Clin Psychopharmacol</i>. 2000;20(1):7-11. doi:10.1097/00004714-200002000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/10653202/pubmed" id="10653202" target="_blank">10653202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29143367">
<a name="29143367"></a>Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. <i>Int J Geriatr Psychiatry.</i> 2018;33(4):583-590. doi: 10.1002/gps.4821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/29143367/pubmed" id="29143367" target="_blank">29143367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1516609">
<a name="1516609"></a>Scavone JM, Greenblatt DJ, Goddard JE, Friedman H, Harmatz JS, Shader RI. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state. <i>Eur J Clin Pharmacol.</i> 1992;42(4):439-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1516609/pubmed" id="1516609" target="_blank">1516609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3680603">
<a name="3680603"></a>Scavone JM, Greenblatt DJ, Shader RI. Alprazolam kinetics following sublingual and oral administration. <i>J Clin Psychopharmacol</i>. 1987;7(5):332-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3680603/pubmed" id="3680603" target="_blank">3680603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1880224">
<a name="1880224"></a>Schmith VD, Piraino B, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease: I. Pharmacokinetics. <i>J Clin Pharmacol</i>. 1991;31(6):571-579. doi:10.1002/j.1552-4604.1991.tb03740.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1880224/pubmed" id="1880224" target="_blank">1880224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1587068">
<a name="1587068"></a>Schmith VD, Piraino B, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease. II. Pharmacodynamics. <i>Clin Pharmacol Ther.</i> 1992;51(5):533-540. doi:10.1038/clpt.1992.59<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1587068/pubmed" id="1587068" target="_blank">1587068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3931145">
<a name="3931145"></a>Seidel WF, Cohen SA, Wilson L, Dement WC. Effects of alprazolam and diazepam on the daytime sleepiness of non-anxious subjects. <i>Psychopharmacology (Berl)</i>. 1985;87(2):194-197. doi:10.1007/BF00431806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3931145/pubmed" id="3931145" target="_blank">3931145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24977401">
<a name="24977401"></a>Shavakhi A, Soleiman S, Gholamrezaei A, et al. Premedication with sublingual or oral alprazolam in adults undergoing diagnostic upper gastrointestinal endoscopy. <i>Endoscopy</i>. 2014;46(8):633‐639. doi:10.1055/s-0034-1377305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/24977401/pubmed" id="24977401" target="_blank">24977401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1684083">
<a name="1684083"></a>Sheehan MF, Sheehan DV, Torres A, Coppola A, Francis E. Snorting benzodiazepines.<i> Am J Drug Alcohol Abuse</i>. 1991;17(4):457-468. doi:10.3109/00952999109001605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1684083/pubmed" id="1684083" target="_blank">1684083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8803653">
<a name="8803653"></a>Shioiri T, Kita N, Takahashi S. Two cases of alprazolam-induced hyperprolactinemia in patients with panic disorder. <i>Int Clin Psychopharmacol</i>. 1996;11(2):149-152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/8803653/pubmed" id="8803653" target="_blank">8803653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3661967">
<a name="3661967"></a>Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzodiazepines--a genetically determined phenomenon? <i>Anaesth Intensive Care</i>. 1987;15(3):330-331. doi:10.1177/0310057X8701500314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3661967/pubmed" id="3661967" target="_blank">3661967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1537778">
<a name="1537778"></a>Simeon JG, Ferguson HB, Knott V, et al, “Clinical, Cognitive, and Neurophysiological Effects of Alprazolam in Children and Adolescents With Overanxious and Avoidant Disorders,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1992, 31(1):29-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1537778/pubmed" id="1537778" target="_blank">1537778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3114808">
<a name="3114808"></a>Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. <i>Psychopharmacology (Berl)</i>. 1987;93(1):105-112. doi: 10.1007/BF02439595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/3114808/pubmed" id="3114808" target="_blank">3114808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6152055">
<a name="6152055"></a>Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. <i>Psychopharmacology (Berl)</i>. 1984;84(4):452-456. doi:10.1007/BF00431449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/6152055/pubmed" id="6152055" target="_blank">6152055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.1">
<a name="Stein.1"></a>Stein MB, Goin MK, Pollack MH, et al; Work Group on Panic Disorder; Steering Committee on Practice Guidelines. American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2nd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed May 28, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/Stein.1/pubmed" id="Stein.1" target="_blank">Stein.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36520439">
<a name="36520439"></a>Sundbakk LM, Gran JM, Wood ME, Handal M, Skurtveit S, Nordeng H. Association of prenatal exposure to benzodiazepines and z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood. <i>JAMA Netw Open</i>. 2022;5(12):e2246889. doi:10.1001/jamanetworkopen.2022.46889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/36520439/pubmed" id="36520439" target="_blank">36520439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22059800">
<a name="22059800"></a>Sylvestre MP, Abrahamowicz M, Čapek R, Tamblyn R. Assessing the cumulative effects of exposure to selected benzodiazepines on the risk of fall-related injuries in the elderly. <i>Int Psychogeriatr</i>. 2012;24(4):577-586. doi:10.1017/S1041610211002031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/22059800/pubmed" id="22059800" target="_blank">22059800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35909254">
<a name="35909254"></a>Szpunar MJ, Freeman MP, Kobylski LA, et al. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. <i>Depress Anxiety</i>. 2022;39(12):751-759. doi:10.1002/da.23280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/35909254/pubmed" id="35909254" target="_blank">35909254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21353710">
<a name="21353710"></a>Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. <i>Trends Neurosci</i>. 2011;34(4):188-197. doi:10.1016/j.tins.2011.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/21353710/pubmed" id="21353710" target="_blank">21353710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891943">
<a name="30891943"></a>Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2019;111(10):613-620. doi:10.1002/bdr2.1497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/30891943/pubmed" id="30891943" target="_blank">30891943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10580363">
<a name="10580363"></a>Tsuda M, Shimizu N, Suzuki T. Contribution of glutamate receptors to benzodiazepine withdrawal signs. <i>Jpn J Pharmacol</i>. 1999;81(1):1-6. doi:10.1254/jjp.81.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/10580363/pubmed" id="10580363" target="_blank">10580363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VA.DoD.1">
<a name="VA.DoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf</a>. Updated June 2017. Accessed March 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VA.DoD.2">
<a name="VA.DoD.2"></a>US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. <a href="https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf</a>. Published August 2021. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11314681">
<a name="11314681"></a>van Laar M, Volkerts E, Verbaten M. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. <i>Psychopharmacology (Berl)</i>. 2001;154(2):189-197. doi:10.1007/s002130000633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/11314681/pubmed" id="11314681" target="_blank">11314681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15266351">
<a name="15266351"></a>Van Sickle BJ, Xiang K, Tietz EI. Transient plasticity of hippocampal CA1 neuron glutamate receptors contributes to benzodiazepine withdrawal-anxiety. <i>Neuropsychopharmacology</i>. 2004;29(11):1994-2006. doi:10.1038/sj.npp.1300531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/15266351/pubmed" id="15266351" target="_blank">15266351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14978513">
<a name="14978513"></a>Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. <i>CNS Drug Rev</i>. 2004;10(1):45-76. doi:10.1111/j.1527-3458.2004.tb00003.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/14978513/pubmed" id="14978513" target="_blank">14978513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29851670">
<a name="29851670"></a>Vicente Ferreira Naves P, Calderaro M, Caboclo LO. De novo myoclonic status epilepticus after benzodiazepine withdrawal. <i>Clin Neuropharmacol</i>. 2018;41(4):142-144. doi:10.1097/WNF.0000000000000283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/29851670/pubmed" id="29851670" target="_blank">29851670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22536226">
<a name="22536226"></a>Vinkers CH, Olivier B. Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective (A) Receptor Modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:416864.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/22536226/pubmed" id="22536226" target="_blank">22536226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35367514">
<a name="35367514"></a>Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: a systematic review. <i>Neurosci Biobehav Rev</i>. 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/35367514/pubmed" id="35367514" target="_blank">35367514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2307974">
<a name="2307974"></a>Warner MD, Peabody CA, Boutros NN, Whiteford HA. Alprazolam and withdrawal seizures. <i>J Nerv Ment Dis</i>. 1990;178(3):208-209. doi:10.1097/00005053-199003000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/2307974/pubmed" id="2307974" target="_blank">2307974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17894421">
<a name="17894421"></a>Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. <i>Pharmacoepidemiol Drug Saf</i>. 2007;16(11):1203-1210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/17894421/pubmed" id="17894421" target="_blank">17894421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31271339">
<a name="31271339"></a>Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. <i>J Psychopharmacol</i>. 2019;33(8):923-947. doi:10.1177/0269881119855343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/31271339/pubmed" id="31271339" target="_blank">31271339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1686752">
<a name="1686752"></a>Wolf B, Griffiths RR. Physical dependence on benzodiazepines: differences within the class. <i>Drug Alcohol Depend</i>. 1991;29(2):153-156. doi:10.1016/0376-8716(91)90044-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alprazolam-drug-information/abstract-text/1686752/pubmed" id="1686752" target="_blank">1686752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xanax.1">
<a name="Xanax.1"></a>Xanax concentrate (alprazolam) [prescribing information]. Eatontown, NJ: West-Ward Phamaceuticals Corp; June 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xanax.2">
<a name="Xanax.2"></a>Xanax (alprazolam) [prescribing information]. New York, NY: Pharmacia and Upjohn Co; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xanax.3">
<a name="Xanax.3"></a>Xanax and Xanax TS (alprazolam) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xanax.4">
<a name="Xanax.4"></a>Xanax XR (alprazolam) [prescribing information]. New York, NY: Pharmacia and Upjohn Co; January 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8453 Version 661.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
